466 related articles for article (PubMed ID: 25787676)
1. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists.
Sindhu T; Srinivasan P
J Recept Signal Transduct Res; 2017 Apr; 37(2):109-123. PubMed ID: 27267434
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent inhibitors targeting Vibrio harveyi LuxR through shape and e-pharmacophore based virtual screening and its biological evaluation.
Rajamanikandan S; Jeyakanthan J; Srinivasan P
Microb Pathog; 2017 Feb; 103():40-56. PubMed ID: 27939874
[TBL] [Abstract][Full Text] [Related]
4. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
Gertzen CG; Spomer L; Smits SH; Häussinger D; Keitel V; Gohlke H
Eur J Med Chem; 2015 Nov; 104():57-72. PubMed ID: 26435512
[TBL] [Abstract][Full Text] [Related]
5. Discovery of selective farnesoid X receptor agonists for the treatment of hyperlipidemia from traditional Chinese medicine based on virtual screening and in vitro validation.
Chen X; Lu F; Luo G; Ren Y; Ma J; Zhang Y
J Biomol Struct Dyn; 2020 Sep; 38(15):4461-4470. PubMed ID: 31842697
[TBL] [Abstract][Full Text] [Related]
6. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
[TBL] [Abstract][Full Text] [Related]
7. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V
J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists.
Sindhu T; Srinivasan P
J Recept Signal Transduct Res; 2014 Aug; 34(4):241-53. PubMed ID: 25072161
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
Fu J; Si P; Zheng M; Chen L; Shen X; Tang Y; Li W
Bioorg Med Chem Lett; 2012 Nov; 22(22):6848-53. PubMed ID: 23040732
[TBL] [Abstract][Full Text] [Related]
11. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
Sato H; Macchiarulo A; Thomas C; Gioiello A; Une M; Hofmann AF; Saladin R; Schoonjans K; Pellicciari R; Auwerx J
J Med Chem; 2008 Mar; 51(6):1831-41. PubMed ID: 18307294
[TBL] [Abstract][Full Text] [Related]
12. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.
Zhu J; Ye Y; Ning M; Mándi A; Feng Y; Zou Q; Kurtán T; Leng Y; Shen J
ChemMedChem; 2013 Jul; 8(7):1210-23. PubMed ID: 23757200
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
15. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
Kumar R; Garg P; Bharatam PV
J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
[TBL] [Abstract][Full Text] [Related]
16. The first pharmacophore model for potent G protein-coupled receptor 119 agonist.
Zhu X; Huang D; Lan X; Tang C; Zhu Y; Han J; Huang W; Qian H
Eur J Med Chem; 2011 Jul; 46(7):2901-7. PubMed ID: 21524831
[TBL] [Abstract][Full Text] [Related]
17. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
18. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
[TBL] [Abstract][Full Text] [Related]
19. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
Sepe V; Renga B; Festa C; D'Amore C; Masullo D; Cipriani S; Di Leva FS; Monti MC; Novellino E; Limongelli V; Zampella A; Fiorucci S
J Med Chem; 2014 Sep; 57(18):7687-701. PubMed ID: 25162837
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid
Nath V; Ahuja R; Kumar V
J Biomol Struct Dyn; 2019 Sep; 37(14):3764-3787. PubMed ID: 30252605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
